GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Cash Conversion Cycle

Faron Pharmaceuticals Oy (LSE:FARN) Cash Conversion Cycle : 0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Faron Pharmaceuticals Oy's Days Sales Outstanding for the six months ended in Dec. 2023 was 0.
Faron Pharmaceuticals Oy's Days Inventory for the six months ended in Dec. 2023 was 0.
Faron Pharmaceuticals Oy's Days Payable for the six months ended in Dec. 2023 was 0.
Therefore, Faron Pharmaceuticals Oy's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2023 was 0.00.


Faron Pharmaceuticals Oy Cash Conversion Cycle Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Cash Conversion Cycle Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Faron Pharmaceuticals Oy Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Faron Pharmaceuticals Oy's Cash Conversion Cycle

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faron Pharmaceuticals Oy's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Cash Conversion Cycle falls into.



Faron Pharmaceuticals Oy Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Faron Pharmaceuticals Oy's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+0-0
=0.00

Faron Pharmaceuticals Oy's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Faron Pharmaceuticals Oy  (LSE:FARN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Faron Pharmaceuticals Oy Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Traded in Other Exchanges
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines